Recurrent Ovarian Endometrioid Adenocarcinoma (DBCOND0113753)
Identifiers
- Synonyms
- Not Available
Associated Data
- Indicated Drugs and Targets
- Not Available
- Clinical Trials
Identifier Title Drug(s) Purpose Phase Status NCT02446600 Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer treatment 3 active_not_recruiting NCT05231122 Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer treatment 2 recruiting NCT04739800 Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents treatment 2 active_not_recruiting NCT02839707 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer treatment 2 / 3 active_not_recruiting NCT04092270 A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer treatment 1 recruiting NCT05920798 A Study of FRaDCs for Ovarian Cancer treatment 1 / 2 recruiting NCT03348631 Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer treatment 2 active_not_recruiting NCT04034927 Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer treatment 2 active_not_recruiting NCT05295589 Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy treatment 2 withdrawn